

May 22, 2025

Q4FY25 Result Update

🗹 Change in Estimates | 🔳 Target | 🔳 Reco

Change in Estimates

	Cu	rrent	Pre	vious
	FY26E	FY27E	FY26E	FY27E
Rating	В	UY	E	BUY
Target Price	1,3	300	1,	300
Sales (Rs. m)	1,11,589	1,31,708	1,11,535	1,31,643
% Chng.	-	-		
EBITDA (Rs. m)	29,601	36,616	29,602	36,612
% Chng.	-	-		
EPS (Rs.)	20.4	26.8	20.5	26.9
% Chng.	(0.3)	(0.2)		

Key Financials - Consolidated

-				
Y/e Mar	FY24	FY25	FY26E	FY27E
Sales (Rs. m)	68,490	86,670	1,11,589	1,31,708
EBITDA (Rs. m)	19,070	23,170	29,601	36,616
Margin (%)	27.8	26.7	26.5	27.8
PAT (Rs. m)	12,780	14,880	19,873	26,084
EPS (Rs.)	13.1	15.3	20.4	26.8
Gr. (%)	(3.9)	16.4	33.6	31.3
DPS (Rs.)	1.0	1.7	2.8	3.4
Yield (%)	0.1	0.1	0.2	0.3
RoE (%)	15.5	15.0	17.4	19.5
RoCE (%)	16.9	16.3	18.2	20.7
EV/Sales (x)	16.2	13.0	10.1	8.4
EV/EBITDA (x)	58.2	48.6	37.9	30.3
PE (x)	86.9	74.6	55.9	42.6
P/BV (x)	11.9	10.5	9.1	7.6

Key Data	MAXI.BO MAXHEALT IN
52-W High / Low	Rs.1,228 / Rs.743
Sensex / Nifty	81,597 / 24,813
Market Cap	Rs.1,110bn/ \$ 12,964m
Shares Outstanding	972m
3M Avg. Daily Value	Rs.2712.36m

Shareholding Pattern (%)

Promoter's	23.74
Foreign	54.74
Domestic Institution	17.58
Public & Others	3.94
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	6.4	15.3	36.8
Relative	3.6	9.1	24.0

Param Desai

paramdesai@plindia.com | 91-22-66322259

Sanketa Kohale sanketakohale@plindia.com | 91-22-66322426

Max Healthcare Institute (MAXHEALT IN)

Rating: BUY | CMP: Rs1,142 | TP: Rs1,300

In-line quarter; expansion plan on track

Quick Pointers:

- ~1,500-bed expansion underway in FY26 at Max Smart, Nanavati, Mohali and a greenfield unit in Gurgaon.
- Dwarka unit achieved break-even vs loss of Rs50mn in Q3.

Max Healthcare Institute (MAXHEALT) reported healthy EBITDA growth of 26% YoY to Rs 6.32bn; in line with our estimates. The company showed phenomenal growth (18% EBITDA CAGR) over FY22-24, despite negligible capacity additions. We expect pick-up in the growth momentum given 1) strong expansion plans (+3500 additional beds over FY24-27E), 2) improving payor mix and 3) Bolt on acquisitions like recently added in Lucknow, Nagpur and Noida. Operational efficiency has also been commendable, especially in competitive markets like NCR. Our FY26E/27E EBITDA remains unchanged and we expect EBITDA/PAT to grow ~2x over FY24-27E. We ascribe 35x EV/EBITDA based on FY27E. Maintain 'BUY' rating with TP of Rs. 1,300/share.

- In line EBITDA, existing units EBITDA grew by 13% YoY: Base business's EBITDA improved 13% YoY to Rs. 5.65bn with margins flat YoY to 27.2% in Q4. During Q4, total of 188 additional beds were commissioned across Lucknow, Dwarka, and BLK. The greenfield Dwarka facility, which was commercialized in Q2, achieved EBITDA breakeven in Q4. New units which now comprise of Noida, Lucknow and Nagpur contributed EBITDA of Rs 670mn (vs Rs 650mn QoQ). Overall margins were flat QoQ to 27.2%. Consol occupancies were steady YoY and QoQ at 75% given the new beds consolidation. ARPOB was flat YoY and improved ~2% QoQ to Rs 77.1K. Existing units ARPOB came in at Rs83.8k; up 7% YoY.
- Robust revenues across existing and new units: Consolidated revenues came at Rs. 23.3bn (up 29% YoY); of which Rs.1.2bn, Rs. 1bn, Rs. 780mn and Rs. 550mn were contributed by Noida, Lucknow, Dwarka and Nagpur units respectively. Revenue growth from existing units were at 13% YoY. Institutional revenue share was at 20.8%. Max Lab and Max@Home revenue stood at Rs 460mn and Rs 560mn respectively. During Q4, net debt decreased by Rs. 320mn QoQ to Rs15.8bn.
- Key con-call takeaways: Expansion plans- Three new brownfield towers at Max Smart, Nanavati, and Mohali (combined ~1,500 additional beds) will be operational over the next 3 months, with the Gurgaon greenfield facility on track for completion by FY26 end. Dwarka (303 beds): Newly operationalized asset light unit reported Rs 1.71bn of revenues and Rs 290mn of EBITDA loss for FY25. An additional 68 beds are set to be operationalized, with plans to expand further by 200 beds. Plans to commission Onco block in Q3FY26. Jaypee Noida: Reported Rs 2.28bn in revenue with a 21% EBITDA margin. Further margin expansion is expected through benefit from higher ARPOB and utilization. Lucknow (Phase 2): Added 128 beds on 9-12 floors through internal configuration along with 35 bed addition was done in May and plans to add another 39 beds in a year. Mgmt plans to add Onco block by Q2FY26.



Nagpur (127 beds): 12 beds added in Oct 2024 and for balance beds are pending for EC approval; completion expected in 24 months. Sec56, Gurgaon (501 beds): Structural work in progress, 1st phase with 300 beds expected to be completed by end of Q3FY26. Nanavati (Phase 1 with 268 beds): Interior work in progress, expected commissioning in the next 90 days. Mohali (155 beds): Finishing work underway, expected commissioning in the next 90 days and plans to add 45beds post-internal reconfiguration. Zirakpur, Mohali (asset-light) 400 beds: Awaiting EC approval; tendering initiated and expected completion in the next 30 months. Max Smart (400 beds): Delayed by a guarter with interior and fit-outs ongoing; on track for completion in Q2FY26. MAX Vikrant (550 beds): Awaiting Forest department clearance for tree transplantation and guided completion by 2028. Max Vaishali (Brownfield) 140 beds - Land parcel acquired, drawings underway and expected completion in ~30 months. Currently existing unit operating at 83% occupancy. Capex of Rs 11.8bn deployed in FY25 towards ongoing expansion projects and upgradation of facilities at acquired hospitals. While generated free cash flows from operations of Rs. 14.5bn and distributed divided of Rs. 1.5bn for FY25. International patient revenue was at Rs 2bn; up 28%YoY despite reduced footfalls from Bangladesh and Yemen due to geopolitical challenges. The segment continues to be a key growth lever.


Exhibit 1: Q4FY25 Result Overview (Rs mn) -In line EBITDA

Y/e March	4QFY25	4QFY24	YoY gr. (%)	3QFY25	QoQ gr. (%)	FY25	FY24	YoY gr. (%)
Net Sales	23,260	18,000	29.2	22,810	2.0	86,670	68,490	26.5
COGS	9,170	7,070	29.7	8,830	3.9	21,150	16,350	29.4
% of Net Sales	39.4	39.3		38.7		24.4	23.9	
Other Expenses	7,770	5,900	31.7	7,760	0.1	42,350	33,070	28.1
% of Net Sales	33.4	32.8		34.0		71.7	56.0	
Total	16,940	12,970	30.6	16,590	2.1	63,500	49,420	28.5
EBITDA	6,320	5,030	25.6	6,220	1.6	23,170	19,070	21.5
Margins (%)	27.2	27.9		27.3		26.7	27.8	
Interest	360	(40)	(1,000.0)	350	2.9	840	(380)	(321.1)
Depreciation	1,140	840	35.7	1,060	7.5	4,060	2,840	43.0
PBT	4,820	4,230	13.9	4,810	0.2	18,270	16,610	10.0
Тах	870	870	-	710	22.5	3,390	3,160	7.3
Tax rate %	18.0	20.6		14.8		18.6	19.0	
PAT	3,950	3,360	17.6	4,100	(3.7)	14,880	13,450	10.6
Other comprehensive income/(exp)	-	-	NA	-	NA	-	-	#DIV/0!
EO items	190	250	(24.0)	950	(80.0)	1,540	670	129.9
Reported PAT	3,760	3,110	20.9	3,150	19.4	13,340	12,780	4.4
6								


Source: Company, PL












Source: Company, PL


Exhibit 4: Occupancy was steady YoY due to new unit consolidation



Source: Company, PL







Source: Company, PL

Financials

Income Statement (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
Net Revenues	68,490	86,670	1,11,589	1,31,708
YoY gr. (%)	16.0	26.5	28.8	18.0
Cost of Goods Sold	16,350	21,150	28,455	33,586
Gross Profit	52,140	65,520	83,134	98,123
Margin (%)	76.1	75.6	74.5	74.5
Employee Cost	23,964	26,501	39,056	46,098
Other Expenses	9,107	15,850	14,477	15,409
EBITDA	19,070	23,170	29,601	36,616
YoY gr. (%)	16.6	21.5	27.8	23.7
Margin (%)	27.8	26.7	26.5	27.8
Depreciation and Amortization	2,840	4,060	4,466	4,913
EBIT	16,230	19,110	25,135	31,703
Margin (%)	23.7	22.0	22.5	24.1
Net Interest	(380)	840	600	(500)
Other Income	-	-	-	-
Profit Before Tax	16,610	18,270	24,535	32,203
Margin (%)	24.3	21.1	22.0	24.5
Total Tax	3,160	3,390	4,662	6,119
Effective tax rate (%)	19.0	18.6	19.0	19.0
Profit after tax	13,450	14,880	19,873	26,084
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	12,780	14,880	19,873	26,084
YoY gr. (%)	(3.8)	16.4	33.6	31.3
Margin (%)	18.7	17.2	17.8	19.8
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	12,780	14,880	19,873	26,084
YoY gr. (%)	(3.8)	16.4	33.6	31.3
Margin (%)	18.7	17.2	17.8	19.8
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	12,780	14,880	19,873	26,084
Equity Shares O/s (m)	972	972	972	972
EPS (Rs)	13.1	15.3	20.4	26.8

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
Non-Current Assets				
Gross Block	59,850	89,310	96,924	1,07,011
Tangibles	59,850	89,310	96,924	1,07,011
Intangibles	-	-	-	-
Acc: Dep / Amortization	-	-	-	-
Tangibles	-	-	-	-
Intangibles	-	-	-	-
Net fixed assets	59,850	89,310	96,924	1,07,011
Tangibles	59,850	89,310	96,924	1,07,011
Intangibles	-	-	-	-
Capital Work In Progress	-	-	-	-
Goodwill	42,670	47,950	47,956	47,962
Non-Current Investments	30	40	40	40
Net Deferred tax assets	(370)	(1,510)	(1,510)	(1,510)
Other Non-Current Assets	-	-	-	-
Current Assets				
Investments	-	-	-	-
Inventories	1,060	1,340	2,446	2,887
Trade receivables	9,945	12,585	17,153	16,580
Cash & Bank Balance	12,860	10,110	10,965	14,738
Other Current Assets	-	-	-	-
Total Assets	1,26,415	1,61,335	1,75,484	1,89,219
Equity				
Equity Share Capital	92,950	1,05,330	1,22,481	1,45,299
Other Equity	-	-	-	-
Total Networth	92,950	1,05,330	1,22,481	1,45,299
Non-Current Liabilities				
Long Term borrowings	11,770	24,920	22,920	14,920
Provisions	-	-	-	-
Other non current liabilities	4,610	4,890	4,890	4,890
Current Liabilities				
ST Debt / Current of LT Debt	-	-	-	-
Trade payables	8,069	10,210	13,146	15,516
Other current liabilities	6,046	8,155	4,216	763
Other current habilities	0,010	0,100	1,210	,00

Source: Company Data, PL Research

PL Capital | INSTITUTIONAL

Cash Flow (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
PBT	16,610	18,270	24,535	32,203
Add. Depreciation	2,840	4,060	4,466	4,913
Add. Interest	(380)	840	600	(500)
Less Financial Other Income	-	-	-	-
Add. Other	-	-	-	-
Op. profit before WC changes	19,070	23,170	29,601	36,616
Net Changes-WC	(4,078)	(2,920)	(5,674)	131
Direct tax	(3,160)	(3,390)	(4,662)	(6,119)
Net cash from Op. activities	11,832	16,860	19,266	30,628
Capital expenditures	(16,000)	(28,580)	(12,000)	(15,000)
Interest / Dividend Income	-	-	-	-
Others	(1,089)	(1,089)	(1,089)	(1,089)
Net Cash from Invt. activities	(17,089)	(29,669)	(13,089)	(16,089)
Issue of share cap. / premium	-	-	-	-
Debt changes	4,950	13,150	(2,000)	(8,000)
Dividend paid	(970)	(1,633)	(2,722)	(3,266)
Interest paid	380	(840)	(600)	500
Others	(1,894)	(618)	-	-
Net cash from Fin. activities	2,466	10,058	(5,322)	(10,766)
Net change in cash	(2,790)	(2,750)	855	3,773
Free Cash Flow	(4,168)	(11,720)	7,266	15,628

Y/e Mar	FY24	FY25	FY26E	FY27E
Per Share(Rs)				
EPS	13.1	15.3	20.4	26.8
CEPS	16.1	19.5	25.0	31.9
BVPS	95.6	108.3	126.0	149.5
FCF	(4.3)	(12.1)	7.5	16.1
DPS	1.0	1.7	2.8	3.4
Return Ratio(%)				
RoCE	16.9	16.3	18.2	20.7
ROIC	14.3	12.6	15.3	18.2
RoE	15.5	15.0	17.4	19.5
Balance Sheet				
Net Debt : Equity (x)	0.0	0.1	0.1	-
Net Working Capital (Days)	16	16	21	11
Valuation(x)				
PER	86.9	74.6	55.9	42.6
P/B	11.9	10.5	9.1	7.6
P/CEPS	71.1	58.6	45.6	35.8
EV/EBITDA	58.2	48.6	37.9	30.3
EV/Sales	16.2	13.0	10.1	8.4
Dividend Yield (%)	0.1	0.1	0.2	0.3

Source: Company Data, PL Research

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q1FY25	Q2FY25	Q3FY25	Q4FY25
Net Revenue	19,350	21,250	22,810	23,260
YoY gr. (%)	18.8	22.7	35.1	29.2
Raw Material Expenses	7,730	8,430	8,830	9,170
Gross Profit	11,620	12,820	13,980	14,090
Margin (%)	60.1	60.3	61.3	60.6
EBITDA	4,990	5,660	6,220	6,320
YoY gr. (%)	14.4	13.7	31.8	25.6
Margin (%)	25.8	26.6	27.3	27.2
Depreciation / Depletion	900	970	1,060	1,140
EBIT	4,090	4,690	5,160	5,180
Margin (%)	21.1	22.1	22.6	22.3
Net Interest	80	50	350	360
Other Income	-	-	-	-
Profit before Tax	4,010	4,640	4,810	4,820
Margin (%)	20.7	21.8	21.1	20.7
Total Tax	870	950	710	870
Effective tax rate (%)	21.7	20.5	14.8	18.0
Profit after Tax	3,140	3,690	4,100	3,950
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	2,950	3,490	3,150	3,760
YoY gr. (%)	1.7	2.9	(7.1)	20.9
Margin (%)	15.2	16.4	13.8	16.2
Extra Ord. Income / (Exp)	190	200	950	190
Reported PAT	3,140	3,690	4,100	3,950
YoY gr. (%)	1.6	3.1	19.5	17.6
Margin (%)	16.2	17.4	18.0	17.0
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	3,140	3,690	4,100	3,950
Avg. Shares O/s (m)	-	-	-	-
EPS (Rs)	3.2	3.8	4.2	4.1

Max Healthcare Institute



Max Healthcare Institute

Price Chart





o. Date	Rating	TP (Rs.)	Share Price (Rs.)
08-Ap	or-25 BUY	1,300	1,084
01-Fe	b-25 BUY	1,300	1,061
08-Ja	in-25 BUY	1,200	1,198
08-No	ov-24 BUY	1,200	1,073
07-00	ct-24 BUY	975	926
02-Au	lg-24 BUY	975	916
08-Ju	II-24 BUY	925	914
24-Ma	ay-24 BUY	925	803

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Apollo Hospitals Enterprise	BUY	8,100	6,683
2	Aster DM Healthcare	BUY	620	476
3	Aurobindo Pharma	BUY	1,510	1,097
4	Cipla	BUY	1,730	1,520
5	Divi's Laboratories	Accumulate	6,800	6,280
6	Dr. Reddy's Laboratories	Reduce	1,225	1,156
7	Eris Lifesciences	BUY	1,740	1,444
8	Fortis Healthcare	BUY	760	636
9	HealthCare Global Enterprises	BUY	555	523
10	Indoco Remedies	Hold	325	233
11	Ipca Laboratories	Accumulate	1,700	1,316
12	J.B. Chemicals & Pharmaceuticals	BUY	2,030	1,641
13	Jupiter Life Line Hospitals	BUY	1,720	1,422
14	Krishna Institute of Medical Sciences	BUY	725	656
15	Lupin	BUY	2,400	2,073
16	Max Healthcare Institute	BUY	1,300	1,084
17	Narayana Hrudayalaya	BUY	1,560	1,644
18	Rainbow Children's Medicare	BUY	1,785	1,406
19	Sun Pharmaceutical Industries	BUY	2,275	1,677
20	Sunteck Realty	BUY	650	401
21	Torrent Pharmaceuticals	Accumulate	3,750	3,234
22	Zydus Lifesciences	Accumulate	1,050	841

PL's Recommendation Nomenclature (Absolute Performance)

Buy	:	> 15%
Accumulate	:	5% to 15%
Hold	:	+5% to -5%
Reduce	:	-5% to -15%
Sell	:	< -15%
Not Rated (NR)	:	No specific call on the stock
Under Review (UR)	:	Rating likely to change shortly



ANALYST CERTIFICATION

(Indian Clients)

We/l, Mr. Param Desai- MBA Finance, Ms. Sanketa Kohale- MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai- MBA Finance, Ms. Sanketa Kohale- MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com